Literature DB >> 3016238

5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester.

B L Roth, T Nakaki, D M Chuang, E Costa.   

Abstract

In rat aorta, 5-hydroxytryptamine (5-HT) stimulated phosphoinositide (PI) turnover and contraction (EC50 = 10 +/- 3 microM); these two responses were highly correlated (r = 0.95; P less than .01). We have characterized the inhibitory potency of a variety of 5-HT-antagonists against the stimulation of PI turnover elicited by 5-HT. Classic 5-HT2 antagonists mianserin, ketanserin, metergoline and pizotifen were found to inhibit this response in the low nanomolar range; amitryptiline and haloperidol were 10- to 20-fold less potent. The alpha-1 receptor antagonist, prazosin, was inactive in micromolar concentrations. The potency of the 5-HT2 antagonists was correlated with their ability to displace [3H] ketanserin binding from rat frontal cortex membranes (r = 0.90; P less than .05). The tumor promoter phorbol dibutyrate was found to inhibit 5-HT-stimulated PI turnover at low nanomolar concentrations whereas the biologically inactive substance 4-alpha-phorbol was ineffective. Pretreatment of rat aorta with phorbol dibutyrate at concentrations that inhibited 5-HT-induced PI turnover also attenuated the aortic contraction induced by 5-HT in the presence of a calcium channel blocker nitrendipine. Our results suggest that phorbol esters may desensitize 5-HT2-receptor-mediated PI turnover and contraction of rat aorta, possibly via an activation of protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016238

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.

Authors:  P A Pierce; J Y Kim; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

2.  Central serotonin receptors: effector systems, physiological roles and regulation.

Authors:  P J Conn; E Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation.

Authors:  Bryan L Roth
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

Review 4.  Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases.

Authors:  John A Allen; Prem N Yadav; Bryan L Roth
Journal:  Neuropharmacology       Date:  2008-07-02       Impact factor: 5.250

5.  Serotonin regulates 6-phosphofructo-1-kinase activity in a PLC-PKC-CaMK II- and Janus kinase-dependent signaling pathway.

Authors:  Wagner Santos Coelho; Mauro Sola-Penna
Journal:  Mol Cell Biochem       Date:  2012-09-26       Impact factor: 3.396

6.  The signal transducing system coupled to serotonin-S2 receptors.

Authors:  D de Chaffoy de Courcelles; J E Leysen; F de Clerck
Journal:  Experientia       Date:  1988-02-15

7.  5-hydroxytryptamine-stimulated accumulation of 1,2-diacylglycerol in the rabbit basilar artery: a role for protein kinase C in smooth muscle contraction.

Authors:  A H Clark; C J Garland
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

8.  Mechanism of cellular effect of phorbol esters on action of arginine vasopressin and angiotensin II on rat vascular smooth muscle cells in culture.

Authors:  C Caramelo; P Tsai; R W Schrier
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

Review 9.  Pharmacosynthetics: Reimagining the pharmacogenetic approach.

Authors:  Martilias S Farrell; Bryan L Roth
Journal:  Brain Res       Date:  2012-10-09       Impact factor: 3.252

Review 10.  Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.

Authors:  Herbert Y Meltzer; Bryan L Roth
Journal:  J Clin Invest       Date:  2013-12-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.